Radeberg, Germany Clinical Trials

A listing of Radeberg, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 56 clinical trials
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828 at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will …

myeloid neoplasm
lymphoid malignancy
FGFR1
Universitaetsklinikum Leipzig
 (6.7 away) Contact site
  • 79 views
  • 14 Dec, 2020
  • +34 other locations
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack …

troponin
clot
aspirin
ck-mb
angiography
Krankenhaus Dresden-Friedrichstadt
 (9.3 away) Contact site
  • 57 views
  • 09 Jun, 2021
  • +192 other locations
Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

The primary objective is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in Cohort 3 of this study.

Universit tsklinik Dresden
 (8.8 away) Contact site
  • 0 views
  • 16 May, 2021
  • +30 other locations
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

For Groups 1 to 4, the primary objective of this study is to estimate the clinical benefit of cemiplimab monotherapy for patients with: metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC. For Group 6, the primary objective is to provide additional efficacy and safety …

Universit tsklinikum Carl Gustav Carus
 (7.4 away) Contact site
  • 0 views
  • 28 Jan, 2021
  • +102 other locations
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Klinische Forschung Dresden GmbH (KFGN)
 (9.2 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +122 other locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with …

University Hospital Carl Gustav Carus Dresden
 (8.8 away) Contact site
  • 2 views
  • 05 Jun, 2021
  • +77 other locations
Efficacy Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

Randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor & licogliflozin combination therapy and each monotherapy, compared with placebo for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis

Novartis Investigative Site
 (7.4 away) Contact site
  • 24 views
  • 16 Jun, 2021
  • +92 other locations
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

A randomized, open-label assessor blinded, multi-center, controlled phase II Trial to evaluate the efficacy of AOP2014 administered bi-weekly subcutaneously (s.c.) in preventing molecular relapse (loss of MMR) in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5, or MR5).

BAG / Onkologische Gemeinschaftspraxis
 (7.4 away) Contact site
  • 22 views
  • 25 Jan, 2021
  • +47 other locations
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell Infiltration.

Dresden, Onkologische Gemeinschaftspraxis
 (7.4 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +13 other locations
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody

avelumab
metastatic merkel cell carcinoma
Universit tsklinikum Dresden
 (8.8 away) Contact site
  • 0 views
  • 15 Jun, 2021
  • +44 other locations